CN109200050B - 一类生物碱在逆转肺癌顺铂耐药性方面的应用 - Google Patents
一类生物碱在逆转肺癌顺铂耐药性方面的应用 Download PDFInfo
- Publication number
- CN109200050B CN109200050B CN201811069730.1A CN201811069730A CN109200050B CN 109200050 B CN109200050 B CN 109200050B CN 201811069730 A CN201811069730 A CN 201811069730A CN 109200050 B CN109200050 B CN 109200050B
- Authority
- CN
- China
- Prior art keywords
- cisplatin
- lung cancer
- drug resistance
- alkaloid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | IC50值(μg/ml) | 组别 | IC50值(μg/ml) |
H460组 | 14.21±1.25 | TB-3给药组 | 20.06±1.19 |
H460/DDP组 | 52.85±1.63 | TB-4给药组 | 48.72±1.55 |
TA-1给药组 | 21.07±1.47 | TC-1给药组 | 7.61±0.93 |
TA-2给药组 | 23.42±1.38 | TD-1给药组 | 7.33±0.88 |
TB-1给药组 | 18.95±1.10 | TE-1给药组 | 15.62±1.27 |
TB-2给药组 | 17.18±1.08 | TE-2给药组 | 9.24±0.96 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811069730.1A CN109200050B (zh) | 2018-09-13 | 2018-09-13 | 一类生物碱在逆转肺癌顺铂耐药性方面的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811069730.1A CN109200050B (zh) | 2018-09-13 | 2018-09-13 | 一类生物碱在逆转肺癌顺铂耐药性方面的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109200050A CN109200050A (zh) | 2019-01-15 |
CN109200050B true CN109200050B (zh) | 2020-11-20 |
Family
ID=64983712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811069730.1A Expired - Fee Related CN109200050B (zh) | 2018-09-13 | 2018-09-13 | 一类生物碱在逆转肺癌顺铂耐药性方面的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109200050B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112933110A (zh) * | 2021-02-03 | 2021-06-11 | 温州医科大学附属第六医院 | 一种用于肺癌患者对于化疗药物敏感性标记物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102008475A (zh) * | 2010-09-09 | 2011-04-13 | 汕头大学医学院 | 喹诺里西啶生物碱在制备用于治疗肿瘤药物的应用 |
CN103509021A (zh) * | 2012-06-21 | 2014-01-15 | 上海药明康德新药开发有限公司 | 金雀花碱衍生物及其制备方法和抗癌作用研究 |
CN106913571A (zh) * | 2017-04-19 | 2017-07-04 | 山西大学 | 一种用于治疗肿瘤的药物及其应用 |
-
2018
- 2018-09-13 CN CN201811069730.1A patent/CN109200050B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102008475A (zh) * | 2010-09-09 | 2011-04-13 | 汕头大学医学院 | 喹诺里西啶生物碱在制备用于治疗肿瘤药物的应用 |
CN103509021A (zh) * | 2012-06-21 | 2014-01-15 | 上海药明康德新药开发有限公司 | 金雀花碱衍生物及其制备方法和抗癌作用研究 |
CN106913571A (zh) * | 2017-04-19 | 2017-07-04 | 山西大学 | 一种用于治疗肿瘤的药物及其应用 |
Non-Patent Citations (2)
Title |
---|
Cytisine induces endoplasmic reticulum stress caused by calcium overload in HepG2 cells;LEI YU et al;《ONCOLOGY REPORTS》;20180331;第39卷(第3期);全文 * |
Multidrug resistance reversal activity of total alkaloid from Fritillaria thunb on cisplatin-resistant human lung adenocarcinoma A549/DDP cells;李泽慧等;《中国药理学与毒理学杂志》;20130630;第27卷(第3期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN109200050A (zh) | 2019-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016062287A1 (zh) | 山喜多药物在用于制备抑制癌症的医药组合物中的用途 | |
Pan et al. | Gambogic Acid Induces Cell Apoptosis and Inhibits MAPK Pathway in PTEN−/−/p53−/− Prostate Cancer Cells In Vitro and Ex Vivo | |
CN101332301A (zh) | 一种抗肿瘤组合物及其应用 | |
CN109200050B (zh) | 一类生物碱在逆转肺癌顺铂耐药性方面的应用 | |
CN102106851A (zh) | 鸦胆苦醇作为化疗药增效剂的应用 | |
CN109172571B (zh) | 一种生物碱用于逆转肺癌顺铂耐药性的用途 | |
CN109172570B (zh) | 一种生物碱在制备防治肺癌患者顺铂耐药性的药物中的应用 | |
CN109045031B (zh) | 一种逆转肺癌顺铂耐药性的生物碱 | |
CN109172569B (zh) | 一种防治肺癌患者顺铂耐药性的生物碱化合物 | |
CN111235218B (zh) | 第三代egfr-tki耐药细胞株及其应用 | |
CN110464722B (zh) | 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用 | |
CN111714480A (zh) | 邻氨基苯甲酸衍生物在制备治疗癌症药物中的用途 | |
CN111499649A (zh) | 一种具有抗肿瘤活性的苯并二呋喃酮类化合物、制备方法及其用途 | |
CN108014105B (zh) | Yd1701在制备治疗aldh1a3高表达肿瘤的药物中的应用 | |
CN107286123B (zh) | 一种二苯呋喃类化合物的制备方法与应用 | |
CN101862313A (zh) | 蒽环类化合物在制备抗乳腺癌药物中的应用 | |
CN106333951B (zh) | 一种mTOR激酶抑制剂与MAPK激酶抑制剂的组合物的应用 | |
CN111298122A (zh) | 用于治疗小细胞肺癌的药物组合物及其应用 | |
JI et al. | Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells. | |
Kui et al. | High‐Throughput Screen of Natural Compounds and Biomarkers for NSCLC Treatment by Differential Expression and Weighted Gene Coexpression Network Analysis (WGCNA) | |
CN111419836B (zh) | 12α-甲氧基-吉玛烷-三烯-12,6α-缩醛的抗人胶质瘤用途 | |
CN114869882B (zh) | 可皆霉素在制备抗肿瘤药物中的应用 | |
CN110420328B (zh) | Syt14抑制剂在制备肺癌治疗药物中的用途 | |
CN109172553B (zh) | 海桐花苷a1用于制备治疗人结肠癌的药物的用途 | |
CN108721260B (zh) | 海桐花苷a1在制备治疗人肝癌的药物方面的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201021 Address after: Room 101, building 132, Baililai scientific innovation town, North Hunan Road, Liaocheng high tech Industrial Development Zone, Shandong Province 252000 Applicant after: Prosense (Shandong) Biomedical Technology Co.,Ltd. Address before: Room 201, 198 Hanhou Avenue, Qingjiangpu District, Huaian City, Jiangsu Province Applicant before: HUAI'AN YITAI BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201120 Termination date: 20210913 |
|
CF01 | Termination of patent right due to non-payment of annual fee |